22.33

1.27% 0.28

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$22.05

Offen:

$21.4

24-Stunden-Volumen:

1.28M

Relative Volume:

0.51

Marktkapitalisierung:

$2.85B

Einnahmen:

$642.82M

Nettoeinkommen (Verlust:

$-43.54M

KGV:

-63.87

EPS:

-0.3496

Netto-Cashflow:

$130.12M

1W Leistung:

+9.30%

1M Leistung:

-3.50%

6M Leistung:

+81.40%

1J Leistung:

+152.32%

1-Tages-Spanne:

$21.11

$22.91

1-Wochen-Bereich:

$19.15

$23.06

52-Wochen-Spanne:

$6.78

$23.56

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1118)

Branche

Health Information Services (51)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,178

Twitter

@10xgenomics

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Compare TXG vs VEEV, TEM, BTSG, HQY, WAY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	22.33	2.85B	642.82M	-43.54M	130.12M	-0.3496
VEEV Veeva Systems Inc	173.98	28.42B	3.20B	908.91M	1.39B	5.4168
TEM Tempus Ai Inc	47.39	8.47B	1.27B	-245.03M	-245.36M	-1.4071
BTSG Brightspring Health Services Inc	43.10	8.28B	12.91B	104.80M	394.69M	0.8769
HQY Healthequity Inc	84.67	7.15B	1.31B	215.20M	408.32M	2.4627
WAY Waystar Holding Corp	23.74	4.55B	1.10B	112.09M	283.19M	0.6096

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-11	Herabstufung	Citigroup	Buy → Neutral
2025-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Eingeleitet	Piper Sandler	Neutral
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Mar 31, 2026

10x Genomics seen as key player in AI-driven biological data buildout - MSN

Mar 31, 2026

10x Genomics (TXG) Receives Upgrade to 'Outperform' by William B - GuruFocus

Mar 31, 2026

10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout10x Genomics (NASDAQ:TXG) - Benzinga

Mar 31, 2026

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know - Yahoo Finance

Mar 27, 2026

Mar 26, 2026

10X Genomics Stock Hits Day Low of $15.90 Amid Price Pressure - Markets Mojo

Mar 26, 2026